Theravance Biopharma (TBPH)
(Delayed Data from NSDQ)
$11.52 USD
+0.31 (2.77%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $11.53 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Fundamental Charts
About Dividend Yield (TTM)
Theravance Biopharma, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Drugs industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
TBPH 11.52 +0.31(2.77%)
Will TBPH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TBPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TBPH
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q2
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
TBPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises
Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y
Other News for TBPH
Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025 | TBPH ...
Theravance Biopharma to Participate in an Upcoming Investor Conference | TBPH Stock News
Theravance Biopharma (TBPH) Target Price Raised to $25 By BTIG | TBPH Stock News
TBPH Stock Price Target Increased Following Milestone Payment | TBPH Stock News
Theravance Biopharma price target raised to $25 from $24 at BTIG